Aconitum Napellus Whole Bryonia Alba Root Cairina
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Aconitum Napellus Whole Bryonia Alba Root Cairina
- Homeopathic Influenza Combination (Multi-Ingredient): Insufficient Data for Repurposing Evaluation
Homeopathic Influenza Combination (Multi-Ingredient): Insufficient Data for Repurposing Evaluation
One-Sentence Summary
This product is a 15-ingredient homeopathic combination that appears formulated for influenza and flu-like symptoms, containing diluted influenza virus strains (A/Darwin/6/2021, B/Austria/1359417/2021, B/Phuket/3073/2013) alongside classical homeopathic botanicals (Gelsemium, Bryonia, Eupatorium, Aconitum). The TxGNN model returned no predicted new indications for this candidate, likely because the multi-ingredient INN string could not be resolved to a single DrugBank node. With 0 clinical trials, 0 publications, and 0 regulatory authorizations identified in this pipeline run, the current evidence base is insufficient to evaluate repurposing potential.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established (no regulatory authorizations found) |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only; in this case, no predictions were generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
This candidate is a homeopathic combination product composed of 15 distinct ingredients, including:
- Homeopathic influenza antigens: Influenza A (A/Darwin/6/2021), Influenza B (B/Austria/1359417/2021 BVR-26, B/Phuket/3073/2013 BVR-1B), and generic Influenza A Whole — consistent with annual seasonal influenza formulations
- Classic homeopathic flu botanicals: Eupatorium perfoliatum (body aches, fever), Gelsemium sempervirens (weakness, headache), Bryonia alba (myalgia, dry cough), Aconitum napellus (sudden fever onset)
- Cairina moschata* (Muscovy duck) heart/liver autolysate: the hallmark ingredient of Oscillococcinum-class homeopathic products
- Additional homeopathic constituents: Ipecac, Phosphorus, Phytolacca americana, Sanguinaria canadensis, Lobaria pulmonaria, Strychnos nux-vomica
The TxGNN knowledge graph operates on individual drug–disease edges indexed by DrugBank ID. Because this candidate:
- Has no resolvable DrugBank ID (the 15-component INN string did not map to any single node), and
- Contains homeopathic dilutions not represented in conventional pharmacological databases,
the graph traversal produced zero candidate disease edges, and no prediction score could be computed.
Clinical Trial Evidence
Currently no related clinical trials registered for this multi-ingredient combination as a unified entity.
Note: Individual components such as influenza virus antigens appear in vaccine trials, but those are not directly applicable to this homeopathic formulation.
Literature Evidence
Currently no related literature available for this specific multi-ingredient combination as identified by the pipeline.
US Market Information
No regulatory authorizations were identified in this pipeline run. This product is classified as not marketed in the United States under this ingredient profile.
Oscillococcinum (Boiron), a related Cairina moschata–based homeopathic product, is marketed in the US as an OTC homeopathic remedy and is regulated under FDA’s OTC homeopathic enforcement policy (2017 revised guidance), but it is a distinct product with a different formulation.
Safety Considerations
Please refer to the package insert for safety information.
No drug–drug interaction data, key warnings, or contraindications were returned by the pipeline. Given the homeopathic nature of the product (ultra-dilute ingredients), conventional pharmacokinetic DDI analysis is generally not applicable. However, some ingredients — notably Aconitum napellus and Strychnos nux-vomica — contain toxic alkaloids (aconitine, strychnine) at pharmacologically active concentrations in non-homeopathic preparations; their safety in this formulation depends entirely on the dilution factor specified in the monograph.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline could not process this candidate because the 15-ingredient INN string cannot be mapped to a single DrugBank node, which is a structural prerequisite for knowledge-graph–based repurposing prediction. Without a valid prediction score or evidence base, no repurposing direction can be evaluated at this time.
To proceed, the following is needed:
- Decompose the combination: Evaluate each of the 15 active ingredients independently through the TxGNN pipeline to identify individual repurposing signals
- Resolve the primary active ingredient: Determine which ingredient is considered the principal agent (likely the influenza virus antigens or Cairina moschata autolysate) and resubmit as a single-INN query
- Clarify regulatory identity: Confirm whether this formulation corresponds to a registered homeopathic OTC product (e.g., Oscillococcinum or equivalent) to enable proper literature and trial linkage
- Obtain the product monograph: Source the full ingredient dilution ratios (e.g., 200CK, 1X) to assess whether any components are present at pharmacologically active concentrations
- Assess MOA plausibility: For the influenza virus antigen components, literature on homeopathic immunomodulation should be reviewed separately from classical pharmacology models
- Address Data Gap DG001 & DG002: Retrieve package insert warnings/contraindications and mechanism-of-action documentation from relevant regulatory sources before any further pipeline evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.